drugset / Trial / NCT06861452
Phase I/IIa Study: RR001 Administered Following Chemotherapy Cycles for Patients With Locally Advanced Pancreatic Carcinoma
Non-randomizedSequentialOpen-labelTreatment
Summary
RR001, a cell-based gene therapy administered following chemotherapy cycles for the treatment of patients with locally advanced pancreatic cancer. Phase I /IIa clinical trial (open label and non-randomized) to test the effects (safety \& efficacy) of increasing doses of RR001
Timeline
- Start
- 2025-06-25
- Primary completion
- 2026-07-29
- Completion
- 2027-01-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RR001 | Cell therapy | 8e+07 cells | Other |
| Subject | RR001 | Cell therapy | 1.6e+08 cells | Other |
| Subject | RR001 | Cell therapy | 2.4e+08 cells | Other |